NSE: INDOUS · BSE: 541304
INDO US BIOTECH LTD
Operates in the agricultural products space, classified under 'Other Agricultural Products' within the broader FMCG sector. Reported FY26 revenue of Rs 110.44 crore with net profit of Rs 13.12 crore. The cost structure is heavily materials-driven at 70.9% of revenue, while employee costs are low at 1.3% and other operating expenses stand at 10.6%. EBITDA margin stood at 15.45% in FY26. The statutory auditor's Emphasis of Matter referenced 'cash sales to farmers', indicating that farmers form part of the customer base. Total assets were Rs 133.10 crore at the end of FY26. The company is listed on both NSE and BSE. No product-level, segment-level, or capacity disclosures are provided in the available filings. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Agricultural products. Materials-heavy agricultural products business with very low employee costs
Exhibit 1: Financial summary, FY21–FY22 (all audited; no estimate years)
| ₹ crore · consolidated | FY21 | FY22 |
|---|---|---|
| Revenue | 40,11,033 | 50 |
| EBITDA (ex other income) | 5,32,575 | — |
| margin % | 13.3 | — |
| Owners' profit | 0 | — |
| EPS, as reported (₹) | 8.07 | 8.27 |
| ROE % · ROCE % | 23.0 · 19.9 | — · 15.0 |
| Debt / equity (x) | 0.50 | — |
| Cash from operations | 43,648 | 3 |
| Capex | (1,95,317) | — |
Exhibit 2: Quarterly performance, last 3 quarters
| ₹ crore | Q4 FY21 | Q2 FY22 | Q4 FY22 |
|---|---|---|---|
| Revenue | 23,24,150 | 25,51,129 | 25 |
| Profit before tax | 2,38,062 | 2,58,761 | 3 |
| Net profit | 3,41,775 | 2,46,261 | — |
| EPS (₹) | 5.63 | 4.06 | 4.21 |
Exhibit 3: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| LT FOODS LIMITED | 14,119 | 22.1 | 3.12 | 12.0 | 13.8 | 16.0 | 18.7 | 11.5 |
| KRBL LIMITED | 8,950 | 11.8 | 1.54 | 9.3 | 11.2 | 14.7 | 8.8 | 24.9 |
| GUJARAT AMBUJA EXPORTS LT | 7,520 | 18.1 | 2.28 | 13.9 | 9.2 | 11.7 | 4.0 | 17.0 |
| TRUALT BIOENERGY LIMITED | 3,590 | 25.6 | 2.27 | 13.7 | 6.1 | 4.8 | — | 23.5 |
| KAVERI SEED CO. LTD. | 3,503 | 14.2 | 2.00 | 9.4 | 16.9 | 17.0 | 6.1 | 40.1 |
| INDRAYANI BIOTECH LTD. | 3,275 | 24.6 | 32.08 | 239.3 | 1.9 | 0.2 | 45.6 | 8.2 |
| AMIR CHAND JAG KUM (E) L | 2,259 | 21.6 | 2.44 | 13.1 | 11.2 | 14.8 | — | 9.5 |
| SANSTAR LIMITED | 2,032 | 60.4 | — | — | — | — | — | 8.8 |
Exhibit 4: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 5.3 | 12.6 | 5 of 53 | 92% |
| ROCE | 12.3 | 4.1 | 23 of 67 | 67% |
| Market cap | 146 | 67 | 28 of 69 | 60% |
Exhibit 5: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 2 Oct 2026 · 22nd AGM voting results - all 5 resolutions passed | board shareholder meetings | low | — | — |
| 30 Sept 2026 · Outcome of 22nd AGM held on Sept 30, 2026 | board shareholder meetings | medium | — | — |
| 28 Sept 2026 · Closure of Trading Window | compliance | minimal | — | — |
| 6 Sept 2026 · 22nd AGM set for September 30 via video conferencing | compliance | minimal | — | — |
| 5 Sept 2026 · Indo Us Bio-Tech submits Annual Report for FY 2025-26 | results | high | — | — |
| 5 Sept 2026 · Book closure Sep 23-30, 2026 for 22nd AGM on Sep 30 | board shareholder meetings | low | — | — |
| 5 Sept 2026 · 22nd AGM on 30 Sep 2026 via video conferencing; auditor, borrowing, related party items | board shareholder meetings | low | — | — |
| 5 Sept 2026 · Board approves AGM on Sep 30, 2026 and appoints new statutory auditor | board shareholder meetings | low | — | — |
| 13 Aug 2026 · Indo US Bio-Tech reports Q1 FY27 results via newspaper filing | compliance | minimal | — | — |
| 12 Aug 2026 · Q1 FY26-27 results: revenue up, profit down year-on-year | results | high | — | — |
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.